Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2011

View Archived Issues

Nycomed and Orion enter agreement for Easyhaler combination products

KBP BioSciences presents new dipeptidyl peptidase 4 inhibitors

Suzhou NeuPharma prepares novel bufalin derivatives

Novel AMPK activators patented by HanAll BioPharma

New muscarinic acetylcholine M1 receptor modulators claimed

Boehringer Ingelheim discloses novel chemokine CXCR3 receptor antagonists

New antibody protects against both group 1 and 2 influenza A viruses in vivo

U.S. researchers investigate fasudil for Parkinson's disease

MDV-3100 blocks breast cancer cell growth in preclinical study

Sanofi reports on phase III CLEAN study of clopidogrel

Study compares PreDx Diabetes Risk Score and metabolic syndrome to predict type 2 diabetes incidence

Acceleron and Celgene enter global collaboration for ACE-536

Dyax treats first patient in phase II trial of ecallantide

Phase IIb trial of cell therapy for venous leg ulcers meets endpoints

Mutations in IRF8 gene correlate with onset of primary immunodeficiencies in humans

Phase II MILLY trial evaluates lebrikizumab in inadequately controlled asthma

Promising results reported on Vibex MTX in rheumatoid arthritis

Prolor Biotech reports encouraging results from phase II hGH-CTP trial

FDA grants orphan drug status to Kamada's AAT product in type 1 diabetes

Development of pramlintide/metreleptin for obesity discontinued

Boehringer Ingelheim obtains E.U. label extension for Pradaxa

Pitavastatin is approved in Mexico for hyperlipidemia

First specific treatment for scorpion stings approved in U.S.

U.S. university evaluates memantine in Down syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...